WEBINAR: How recent legislative changes impact the German P&R landscape

The statutory health insurance financial stabilization act, approved by German Parliament last November, made substantial changes to the characteristics of pricing and reimbursement in Europe’s largest pharmaceutical market. For instance, the new law reduces the free pricing period from 12 to 6 months and changes the guard rails of the additional benefit assessment determining price anchors for pharmaceutical reimbursement prices.
In addition, a recent decision by Germany’s highest social court last week is causing a stir among industry players. The expected verdict on the arbitration board decision on GE Healthcare’s Rapiscan® (regadenoson) has the potential to limit the scope of the benefit assessment determining pharmaceutical reimbursement prices.
Alexander Natz, attorney at law and Secretary General of EUCOPE and Thomas Ecker, health economist and Managing Director at Ecker + Ecker discuss the implications and relevance of the recent legislative changes for a global audience.